Low levels of plasma endothelin-1 in patients with retinitis pigmentosa by Ohguro, Hiroshi et al.
© 2010 Ohguro et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2010:4 569–573
Clinical Ophthalmology
O R I G I N A L   R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
569
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 





1Department of Ophthalmology, 
Sapporo Medical University School 
of Medicine, 2Department of 
Ophthalmology, Keio University 
School of Medicine, 3Department of 
Ophthalmology, Hirosaki University 
School of Medicine, Japan
Correspondence: Hiroshi Ohguro
Department of Ophthalmology, Sapporo 
Medical University School of Medicine, 
South-1, West-16, Chuo-ku, Sapporo, 
Japan 060-8543
Tel +81 11 611 2111 extn 3435
Fax +81 11 613 6575
Email ooguro@sapmed.ac.jp
Purpose: The aim of this study was to elucidate the role of endothelin-1 (ET-1) in the 
pathophysiology of retinitis pigmentosa (RP).
Methods: Plasma ET-1 levels and ophthalmic features in 50 RP patients were compared with 
those in 20 healthy-eye control subjects. Plasma ET-1 concentrations were determined using a 
commercially available enzyme-linked immunosorbent assay kit.
Results: Mean plasma ET-1 levels of RP patients (1.88 ± 0.56 pg/mL) were significantly 
lower than those of control subjects (2.30 ± 0.30 pg/mL, Mann-Whitney’s U test; P  0.01). 
However, ET-1 concentrations varied markedly in each patient. Among RP patients, a significant 
correlation of ET-1 concentrations was not observed in terms of its hereditary forms or other 
clinical factors.
Conclusion: ET-1 may be important in the pathogenesis of RP, and measurement of its plasma 
concentrations may also contribute to additional insights into the retinal hemodynamics of RP.
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Introduction
Retinitis pigmentosa (RP) is a heterogeneous disease group of progressive hereditary 
retinal degeneration. It is clinically characterized by night blindness and peripheral 
concentric visual field defects and abnormal electroretinogram responses due to 
photoreceptor cell degeneration.1 Markedly decreased retinal blood flow has been 
reported.2–5 This suggests that impaired retinal hemodynamics may be involved in 
the pathophysiology of RP. However, the pathologic and biochemical mechanisms 
involved have not yet been elucidated. A preliminary study has demonstrated that 
plasma endothelin-1 (ET-1), a very potent vasoconstrictor, is significantly elevated 
in RP patients when compared with control subjects.6 It was suggested that elevated 
ET-1 could lead to vasoconstriction and decrease in retinal blood flow, resulting 
in further deterioration of retinal degeneration. Thus, it is of much interest to test 
plasma ET-1 levels in various types of RP patients to elucidate the pathophysiologic 
significance of ET-1 in the etiology of RP. In the present study, we investigated 




Fifty RP patients (32 sporadic RP [SRP], nine autosomal dominant RP [ADRP], 
seven autosomal recessive RP [ARRP], one X-linked RP, one Biedl-Bardet 
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Table 1 Clinical characteristics and serum ET-1 levels in 50 RP patients
Age Visual acuity (R/L) Genetic type Visual field MD (dB) (R/L) ET -1 (pg/mL)
71 HM/HM ADRP n.d. 2.14
45 0.02/0.02 ADRP n.d. 1.57
49 0.06/0.06 ADRP n.d. 2.3
50 HM/0.3 ADRP n.d. 0.71
50 0.3/0.3 ADRP -35.36/-35.26 2.63
43 0.1/0.4 ADRP -12.14/-9.12 1.9
72 0.4/0.4 ADRP -16.32/-16.33 1.99
60 0.5/0.5 ADRP -16.21/-19.49 1.66
60 0.7/0.7 ADRP -24.34/-24.60 1.87
52 HM/HM ARRP -35.06/-35.18 2.55
61 0.02/0.02 ARRP n.d. 1.95
72 0.05/0.05 ARRP n.d. 2.18
70 0.1/0.1 ARRP n.d. 1.54
49 0.15/0.15 ARRP -19.90/-19,58 1.8
61 0.2/0.2 ARRP -31.39/-37.72 1.42
50 1.0/0.9 ARP -0.49/-1.78 2.36
63 0.4/0.4 XLRP carrier n.d. 0.83
23 0.05/0.09 Biedl-Bardet n.d. 1.81
75 LP/LP SP n.d. 2.09
65 HM/HM SP n.d. 2.13
34 0.03/0.02 SP -13.07/-16.00 3.44
74 0.09/0.05 SP -15.30/-16.14 1.74
56 0.02/0.1 SP -18.30/-19.61 0.85
80 0.1/0.1 SP n.d. 2.3
71 0.1/0.1 SP -23.46/-22.71 1.88
73 0.2/0.03 SP n.d. 1.11
71 0.2/0.2 SP -27.58/-23.97 1.42
57 0.02/0.2 SP -11.11/-9.84 2.61
49 0.01/0.3 SP -1.97/-3.41 1.23
72 0.1/0.3 SP n.d. 1.74
49 0.2/0.3 SP -27.37/-24.82 0.98
82 0.3/0.3 SP n.d. 1.93
49 0.4/0.3 SP -20.62/-22.50 2.76
59 0.5/0.3 SP -32.02/-33.10 1.45
56 0.4/0.5 SP -31.36/-33.64 1.66
28 0.5/0.4 SP n.d. 1.96
62 0.4/0.5 SP -13.40/-17.64 1.56
76 0.5/0.6 SP -31.66/-31.22 1.67
39 0.7/0.7 SP -10.22/-25.48 1.87
65 0.7/0.7 SP -10.22/-8.66 2.67
74 0.7/0.7 SP -20.91/-3.33 2.42
32 0.8/0.7 SP n.d. 2.05
58 0.8/0.7 SP -8.17/-5.00 2.85
55 0.9/0.9 SP -0.77/-2.10 2.55
34 0.9/0.9 SP -4.44/-6.29 1.84
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Table 1 (Continued )
Age Visual acuity (R/L) Genetic type Visual field MD (dB) (R/L) ET -1 (pg/mL)
28 0.9/0.9 SP -14.39/-16.53 2.09
54 1.2/1.2 SP -8.83/-11.07 1.53
49 1.2/1.2 SP -13.35/-11.51 1.47
27 1.2/1.2 SP -18.74/-14.46 2.06
66 n.d. n.d. n.d. 1.05
Abbreviations: ET-1, endothelin-1; HM, hand motion; LP, light perception; RP, retinitis pigmentosa; ADRP, autosomal dominant RP; ARRP, autosomal recessive RP; SP, sporadic 
RP; XLRP, X-linked RP; n.d., not determined.
syndrome) aged 56.4 ± 15 years, and 20 healthy-eye control 
subjects, aged 55.8 ± 8 years, with no history of systemic 
hypertension or diabetes mellitus were recruited. Informed 
consent was obtained from all subjects. The study was 
performed in accordance with our institution’s guidelines 
and the Declaration of Helsinki on Biomedical Research 
Involving Human Subjects, and the protocol was approved 
by the Clinical Research Ethics Board of the Hirosaki 
University Hospital and Sapporo Medical University 
Hospital, and their Committees for the Protection of 
Human Subjects.
After the subjects had rested in the sitting position for 
30 minutes, venous blood samples (5 mL) were taken and 
plasma was then separated out by centrifugation and frozen 
at -30°C. Prior to measuring the concentration of plasma ET-1, 
the frozen plasma samples were thawed, and subjected to the 
Parameter® (R and D Systems, Minneapolis, MN) human 
ET-1 immunoassay kit. This assay used the quantitative enzyme 
immunoassay technique. An antibody specific for ET-1 was 
precoated onto a microplate. Standards, samples, controls, and 
conjugate were pipetted into wells and any ET-1 present was 
sandwiched by the immobilized antibody and the enzyme-
linked antibody specific for ET-1. Following a wash to remove 
any unbound substances and/or antibody-enzyme reagents, 
substrate was added to the wells and color developed in pro-
portion to the amount of ET-1 binding. The color development 
was stopped and the intensity of the color was measured by 
microplate reader. The measurements were performed in tripli-
cate. Visual fields were examined by Humphrey SITA standard 
10-2 threshold automated perimetry (Humphrey Instruments 
Inc., San Leandro, CA).
Statistical analysis
All values are expressed as the mean ± standard deviation 
(SD) of at least three independent experiments. Data were 
statistically analyzed with the Mann-Whitney U test for 
comparison of all groups. Statistical significance was 
determined as P  0.01.
Results
The clinical characteristics of 50 RP patients including 
genotypes, age, gender, visual acuity, and mean defect (MD) for 
the 10.2 visual field are summarized in Table 1. Mean plasma 
ET-1 concentrations in RP patients (1.88 ± 0.30 pg/mL) were 
lower than those of healthy-eye control subjects (2.30 ± 0.30). 
As shown in Table 1, significantly higher (2.6 pg/mL) and 
lower (2.0 pg/mL) ET-1 concentrations were recognized 
in eight and 31 RP patients, respectively. These levels were 
not statistically different among various genetic types of RP 
(ADRP, ARRP, and SRP).
In terms of the relationship between plasma ET-1 levels 
and clinical factors in RP, mean plasma ET-1 levels of more 
deteriorated in visual acuity (Table 2), and visual field MD 
(Table 3) was lower than those in the relatively preserved 
vision group. However, plasma ET-1 values in each patient 
were variable, and patients with significantly higher and 
lower ET-1 values did not always show better or worse visual 
characteristics as above.
Discussion
ET-1 is produced by vascular endothelial cells and known 
to be a potent vasoconstrictive peptide.7 It has been shown 
that ET-1 receptors are present in human uveal tissues,8 the 
retina, and optic nerve heads,9 suggesting that ET-1 may have 
several physiologic and pathologic roles in the eye. It has 
been previously reported that abnormal plasma ET-1 levels 
are found in several ocular diseases, including glaucoma10,11 
and retinal diseases such as diabetic retinopathy,12 retinal 
vein/artery occlusion, and proliferative vitreoretinopathy,13 
Table 2 Serum ET-1 levels and visual acuity in RP patients
Visual acuity
0.2 0.2–0.6 0.7
Serum ET-1 (pg/mL) 1.81 ± 0.62 1.83 ± 0.51 2.12 ± 0.40
Notes: Better visual acuity among both eyes was enrolled.   A statistically significant 
difference (P  0.01) was observed between 0.2 and 0.7.
Abbreviations: ET-1, endothelin-1; RP, retinitis pigmentosa.Clinical Ophthalmology 2010:4 572
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in which ocular blood circulation is primarily involved in 
their pathology.
It was difficult to determine intraocular concentrations 
of ET-1, because intraocular fluid is necessary. In a previous 
study, it was reported that ET-1 was recognized in the subretinal 
fluid of patients with proliferative vitreoretinopathy, and its 
concentrations were significantly correlated with plasma ET-1 
concentrations.13 If this is the case, because ET-1 within the 
peripheral blood circulation most likely penetrates into the 
intraocular cavity, intraocular ET-1 levels must correlate with 
plasma ET-1 levels. This suggests that ET-1 is indeed involved 
in the pathogenesis of several ocular diseases, including RP, 
and the plasma ET-1 level is a useful marker for evaluation 
of intraocular hemodynamics. Cellini et al have reported that 
plasma ET-1 levels were significantly higher in RP patients 
than those in control subjects,6 suggesting that an increase 
in plasma ET-1 may lead to vasoconstriction, resulting in a 
decrease in retinal blood flow.3 This suggests that abnormally 
higher levels of plasma ET-1 may also be involved in the 
pathology of retinal degenerative disease, in addition to 
the ocular vascular diseases mentioned above. However, in 
the present study, plasma ET-1 levels of RP patients were not 
higher than those in the healthy-eye control subjects, and the 
plasma ET-1 values varied in individual patients. Thus, the 
contribution of plasma ET-1 levels in the etiology of RP may 
not be as important as previously suggested.6 With regard to 
the differences between our data and those of others, several 
possibilities, including different assay systems, race, disease 
heterogeneity, and disease stages may be involved. In terms of 
the assay system used, the plasma ET-1 levels of RP patients 
in our study were comparable with those of Cellini et al but 
those of our control subjects were significantly lower than 
levels reported for previous studies.6,11,14
Marked attenuation of retinal vessels with sclerotic and 
atrophic changes of the choriocapillaris layer have been 
documented in RP.15–17 In addition, several morphologic 
studies have shown thickening of the extracellular matrix 
surrounding retinal vessels, especially in areas where trans-
located retinal pigment epithelial cells are close to the vessels 
following the progressive loss of photoreceptor cells.18 On 
the other hand, several hemodynamic studies have revealed 
that retinal blood flow is markedly decreased in RP patients 
compared with normal control subjects.2–5 This change in 
retinal blood flow is quite reasonable because of signifi-
cant sclerosis of the retinal and choroidal vessels, and the 
lower requirement for blood flow following degeneration of 
  oxygen-consuming photoreceptors and thinning of the outer 
retina. Taking all these observations into consideration, it is 
thought that ET-1 may also be involved in the pathogenesis 
of RP, as postulated by Cellini et al.6 However, the data from 
our present series of patients suggests that its contribution 
may be more complex and variable in such a heterogeneous 
disease group. Thus, evaluating plasma ET-1 levels will con-
tribute to additional insights into the retinal hemodynamics 
of RP and to development of new therapeutic strategies for 
preventing retinal degeneration in RP.
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